Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

× No keyword cloud information.

35 in total

Review 1. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Authors: W J Sandborn; S B Hanauer
Journal: Inflamm Bowel Dis Date: 1999-05 Impact factor: 5.325

2. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors: F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal: Ann Rheum Dis Date: 2000-06 Impact factor: 19.103

3. Ileocolonoscopy in seronegative spondylarthropathy.

Authors: M De Vos; C Cuvelier; H Mielants; E Veys; F Barbier; A Elewaut
Journal: Gastroenterology Date: 1989-02 Impact factor: 22.682

Review 4. Regulation of autoimmunity by proinflammatory cytokines.

Authors: A P Cope
Journal: Curr Opin Immunol Date: 1998-12 Impact factor: 7.486

5. The misconduct of redundant publication.

Authors: M Doherty
Journal: Ann Rheum Dis Date: 1996-11 Impact factor: 19.103

6. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors: R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal: Lancet Date: 1999-12-04 Impact factor: 79.321

7. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

Authors: A Zink; J Braun; J Listing; J Wollenhaupt
Journal: J Rheumatol Date: 2000-03 Impact factor: 4.666

8. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides.

Authors: J Braun; M Tuszewski; S Ehlers; J Häberle; M Bollow; U Eggens; A Distler; J Sieper
Journal: J Rheumatol Date: 1997-06 Impact factor: 4.666

9. The natural disease course of ankylosing spondylitis.

Authors: S Carette; D Graham; H Little; J Rubenstein; P Rosen
Journal: Arthritis Rheum Date: 1983-02

Review 10. The role of tumor necrosis factor in health and disease.

Authors: B A Beutler
Journal: J Rheumatol Suppl Date: 1999-05

3 in total

Review 1. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors: J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103

2. Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.

Authors: Dongyi He; Qi Zhu; Quan Zhou; Qing Qi; Hongmei Sun; Liza M Zachariah; Grace Wang; John D Reveille; Yongtao Guan; Xiaodong Zhou
Journal: Clin Rheumatol Date: 2017-04-22 Impact factor: 2.980

Review 3. [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].

Authors: Hans-Eckhard Langer
Journal: Wien Med Wochenschr Date: 2008

3 in total